Moderna Inc (MRNA)
Profitability ratios
Return on sales
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Gross profit margin | 54.76% | 31.47% | 71.88% | 85.24% | 97.11% |
| Operating profit margin | -121.91% | -61.90% | 48.90% | 74.97% | -278.02% |
| Pretax margin | -111.46% | -57.56% | 49.71% | 74.90% | -271.24% |
| Net profit margin | -110.04% | -68.84% | 43.41% | 68.80% | -272.16% |
Moderna Inc's profitability ratios display a fluctuating trend over the years.
1. Gross Profit Margin: The company's gross profit margin has shown a decline from 97.11% in 2020 to 54.76% in 2024. While it remained high initially, there has been volatility in recent years, indicating potential changes in the cost of goods sold and pricing strategies.
2. Operating Profit Margin: Moderna Inc's operating profit margin experienced significant variability, ranging from -278.02% in 2020 to -121.91% in 2024. The positive margins in 2021 and 2022 suggest the company was able to generate profits from its core operations, but the negative margins in other years point to challenges in controlling operational expenses.
3. Pretax Margin: The pretax margin also exhibited fluctuations, with a low of -271.24% in 2020 and -111.46% in 2024. Positive pretax margins in 2021 and 2022 indicate the company's ability to generate income before accounting for taxes, but the negative margins in other years highlight the impact of expenses and losses on the company's profitability.
4. Net Profit Margin: Moderna Inc's net profit margin fluctuated from -272.16% in 2020 to -110.04% in 2024. The positive net profit margin in 2021 and 2022 suggests the company was able to achieve profitability after accounting for all expenses and taxes. However, the negative margins in other years indicate challenges in generating sufficient bottom-line profits.
Overall, the analysis of Moderna Inc's profitability ratios reflects a volatile performance, with fluctuations in each margin metric over the years. This signals potential challenges in maintaining consistent profitability and efficiency in managing costs and revenues.
Return on investment
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -27.90% | -23.01% | 36.43% | 53.90% | -10.40% |
| Return on assets (ROA) | -25.18% | -25.58% | 32.34% | 49.46% | -10.18% |
| Return on total capital | -32.87% | -28.18% | 49.26% | 94.00% | -29.80% |
| Return on equity (ROE) | -32.67% | -34.03% | 43.73% | 86.26% | -29.17% |
1. Operating Return on Assets (Operating ROA):
- Moderna Inc's Operating ROA has been volatile over the past five years, ranging from negative values to a high of 53.90% in December 2021. This ratio measures the company's operating income generated per dollar of assets, indicating that in 2021 and 2022, the company effectively generated operating income relative to its assets.
2. Return on Assets (ROA):
- Moderna Inc's ROA shows a similar trend to the Operating ROA, with negative values in 2020, 2023, and 2024. The highest value was in 2021 at 49.46%. ROA indicates the company's overall profitability by measuring how efficient it is at utilizing its assets to generate earnings.
3. Return on Total Capital:
- The Return on Total Capital for Moderna Inc has fluctuated significantly, with the highest value in 2021 at 94.00% and negative values in 2020, 2023, and 2024. This ratio evaluates the returns generated from all sources of capital invested in the company, showcasing the company's ability to generate returns for both debt and equity holders.
4. Return on Equity (ROE):
- Moderna Inc's ROE has also varied widely, with a peak of 86.26% in 2021 and negative values in 2020, 2023, and 2024. ROE measures the company's ability to generate profits from shareholders' equity, reflecting how well it is utilizing investor funds to generate earnings.
In conclusion, Moderna Inc's profitability ratios have shown fluctuations over the years, with some years indicating strong profitability while others showing challenges. Further analysis and consideration of the company's financial strategy and industry dynamics would be needed to provide a more comprehensive evaluation of its performance.